We are live on ! Find out more
KCM

Knoll Capital Management Portfolio holdings

AUM $180M
1-Year Est. Return 66.11%
This Fund
S&P 500
This Quarter Est. Return
+27.72%
1 Year Est. Return
+66.11%
3 Year Est. Return
+268.55%
5 Year Est. Return
+741%
10 Year Est. Return
+10,877.35%
AUM
$309M
AUM Growth
+$62.3M
Cap. Flow
+$1.38M
Cap. Flow %
0.45%
Top 10 Hldgs %
98.08%
Holding
23
New
1
Increased
–
Reduced
3
Closed
1

Top Buys

Rank Stock Value
1
NTBL
Notable Labs, Ltd. Ordinary Shares
NTBL
+$3.18M

Top Sells

Rank Stock Value
1
AMPE
Ampio Pharmaceuticals Inc.
AMPE
+$546K
2
GLMD icon
Galmed Pharmaceuticals
GLMD
+$79.4K
3
ZSAN
Zosano Pharma Corporation
ZSAN
+$14.2K

Sector Composition

Rank Sector Weight
1 Healthcare 13.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDVN
1
DELISTED
MEDIVATION, INC.
MDVN
$265M 85.95%
4,397,838
– –
CRBP icon
2
Corbus Pharmaceuticals
CRBP
$170M
$7.67M 2.48%
85,464
– –
TOVX icon
3
Theriva Biologics
TOVX
$10.2M
$6.72M 2.18%
427
– –
ARCT icon
4
Arcturus Therapeutics
ARCT
$157M
$5.01M 1.62%
159,331
– –
AMPE
5
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
$4.18M 1.35%
10,794
-500
-4% -$546K
NTBL
6
DELISTED
Notable Labs, Ltd. Ordinary Shares
NTBL
$3.97M 1.29%
+24,589
New +$3.18M
ABEO icon
7
Abeona Therapeutics
ABEO
$345M
$3.21M 1.04%
54,391
– –
CEMP
8
DELISTED
Cempra, Inc.
CEMP
$2.98M 0.97%
180,800
– –
ADXS
9
DELISTED
Advaxis Inc
ADXS
$2.23M 0.72%
18,333
– –
VNRX icon
10
VolitionRx Ltd
VNRX
$12M
$1.45M 0.47%
23,077
– –
KERX
11
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$1.32M 0.43%
200,000
– –
LUMO
12
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$1.15M 0.37%
11,382
– –
ALDX icon
13
Aldeyra Therapeutics
ALDX
$91.7M
$773K 0.25%
135,800
– –
NBSE
14
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$562K 0.18%
513
– –
ADXSW
15
DELISTED
Advaxis Inc Warrants
ADXSW
$502K 0.16%
112,500
– –
ENLV icon
16
Enlivex Ltd
ENLV
$70.7M
$402K 0.13%
418
– –
EVOK
17
DELISTED
Evoke Pharma
EVOK
$381K 0.12%
387
– –
LSTA icon
18
Lisata Therapeutics
LSTA
$15.2M
$328K 0.11%
3,705
– –
CSBR icon
19
Champions Oncology
CSBR
$85.1M
$239K 0.08%
111,111
– –
GLMD icon
20
Galmed Pharmaceuticals
GLMD
$3.94M
$224K 0.07%
277
-84
-23% -$79.4K
APTO
21
DELISTED
Aptose Biosciences, Inc.
APTO
$29K 0.01%
27
– –
ZSAN
22
DELISTED
Zosano Pharma Corporation
ZSAN
$15K ﹤0.01%
16
-11
-41% -$14.2K

Similar funds

MGWA
Monument Group Wealth Advisors Concord, Massachusetts $180M AUM 19.81% 1-Year Est. Return
AW
Alchemi Wealth Essex, Connecticut $180M AUM
FBC
Fairfield, Bush & Co Darien, Connecticut $180M AUM 39.51% 1-Year Est. Return
AIC
Aurora Investment Counsel Atlanta, Georgia $180M AUM 0.3% 1-Year Est. Return
AG
Amiral Gestion Paris, France $180M AUM 9.43% 1-Year Est. Return
PCA
Prospect Capital Advisors Sausalito, California $180M AUM 60.99% 1-Year Est. Return
HIC
Hamrick Investment Counsel Seattle, Washington $180M AUM
FFA
Frazier Financial Advisors Columbus, Ohio $181M AUM 11.16% 1-Year Est. Return

Knoll Capital Management's Q2 2016 Portfolio in Review

As of Q2 2016, Knoll Capital Management held 23 positions worth $309M, up 25% from $246M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

Knoll Capital Management's Q2 2016 filing shows 1 new, 3 reduced and 1 closed positions. Its largest new stake was Notable Labs, Ltd. Ordinary Shares: 24,589 shares worth $3.97M. The largest sale was Ampio Pharmaceuticals Inc., an estimated $546K.

By sector, the portfolio is most concentrated in Healthcare at 14% of assets, down from 17% a quarter earlier.

  • Knoll Capital Management's largest Q2 2016 buy was Notable Labs, Ltd. Ordinary Shares: 24,589 shares worth $3.97M.
  • Knoll Capital Management's biggest Q2 2016 reduction was Ampio Pharmaceuticals Inc., cutting an estimated $546K.
  • Knoll Capital Management's ten largest holdings make up 98% of its $309M portfolio in Q2 2016.
  • Knoll Capital Management opened 1 new position and closed 1 in Q2 2016.
  • Knoll Capital Management's portfolio value rose 25% quarter-over-quarter to $309M.

Based on Knoll Capital Management's 13F filing for Q2 2016, filed 15 Aug 2016.